The 2003 Fierce 15: Where are they now?

FierceBiotech Fierce 15 WinnersFor the past six years FierceBiotech's annual list of the Fierce 15 has been our single most popular publishing event for readers. And late in the summer, the editors that work on FierceBiotech got together and started a special project, going back over our winners and checking up on where they are now. Our feature begins today, with a look back at the Fierce 15 of 2003.

The 15 biotech companies we chronicled in 2003 have experienced all the thrills, spills and chills any experienced industry analyst has grown accustomed to. There are cautionary tales, last-minute deals that averted disaster and a few that have stayed independent, struck big licensing deals and forged a successful development record that could qualify for a list of the top Fierce 15 companies of all time.

There are lessons aplenty here that would help inspire and terrorize anyone running a biotech company. Every Tuesday for the next six weeks we'll bring you a new edition of the Fierce 15 Revisited. We hope you enjoy the trip down memory lane.

- see the 2003 Fierce 15 revisited
- check out the original report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.